These three people to control stake of Ratan Tata in Tata group companies, not Maya Tata, Leah Tata, Jimmy Tata The boards of the Ratan Tata Endowment Foundation (RTEF) and the Ratan Tata ...

One might think that a pharmaceutical ingredients company that boasts clients in 80 countries, certification from several ...

Tilt your stock portfolio toward biotech companies now and you could stand to make substantial profits in the near future. You can also find cost-effective stocks under $20 to trade daily on the ...

Read on for more. Biotech companies like Absci and Generate:Biomedicines have raised hundreds of millions of dollars by claiming to design novel antibody drugs from scratch using artificial ...

"We are ecstatic to welcome Josh to IDEAYA as we advance our broad potential first-in-class precision medicine oncology pipeline and build a fully integrated biotechnology company. Josh is a ...

Feb. 14 - Kojin: Boston biotech Kojin is winding down operations over the next few months, according to a LinkedIn status from the business. In the post, the company said it expects many of its ...

If these times have anything to say about it, the next Microsoft is coming from the biotech sector. Investors are moving in looking for profits, even putting companies without products on the map.

United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. A biotechnology company in Research Triangle Park has taken a major step to develop a new option for ...

Maya Mehrara is a News Reporter at Newsweek based in London, U.K.. Her focus is reporting on international news. She has covered Ukraine, Russia, immigration issues, and the revolution in Iran.

Showcase your company news with guaranteed exposure both in print and online In today's rapidly evolving business landscape, CFOs are pivotal in driving organizational success through ...

In 2021, the biotech index reached a value of more than $160, as the industry benefitted from investor enthusiasm for companies that could provide therapeutic solutions during the pandemic.

Prior, Bleharski worked as a senior staff scientist at a private biotechnology company in San Diego and was a post-doctoral fellow at the La Jolla Institute for Allergy and Immunology and the UCLA ...